Printer Friendly

FOUNTAIN PHARMACEUTICALS ANNOUNCES REORGANIZATION OF MANAGEMENT

 FOUNTAIN PHARMACEUTICALS ANNOUNCES REORGANIZATION OF MANAGEMENT
 LARGO, Fla., April 10 /PRNewswire/ -- Fountain Pharmaceuticals, Inc. (NASDAQ: FPHI) today announced that it has implemented a reorganization of its management in order to realign certain executive personnel so as to further facilitate the company's continued scientific developments and marketing and sales efforts.
 At a meeting of the board of directors of Fountain yesterday, Clark A. Marcus resigned as chairman and was replaced by Dr. Michael Fountain. In addition, Marcus has resigned as the company's chief operating and chief financial officer. James Fuchs has assumed the office of treasurer.
 According to a spokesman for the company, Marcus has elected to resign as chairman and chief operating and chief financial officer in order to more fully focus his time and attention on the company's worldwide sales and marketing efforts. Marcus will also continue to serve as the company's general counsel.
 Michael Fountain, founder of the company's proprietary encapsulation technologies, has assumed the role of chairman in order to more fully preside over the direction of the company's competitive and scientific posture within the United States and worldwide pharmaceutical communities.
 The said it also company intends to engage a search for additional executive personnel who will be responsible for, among others, supplementing the company's ongoing licensing and business development efforts, as well as undertaking certain administrative responsibilities.
 Fountain Pharmaceuticals, Inc. is a development stage company that specializes in the application of encapsulated drug delivery systems for the purpose of improving drug compound delivery and enhancing effectiveness of existing products. Fountain also develops proprietary products with applications in the human health care and consumer goods industries.
 -0- 4/10/92
 /CONTACT: Dr. Michael Fountain of Fountain Pharmaceuticals Inc. 813-392-5300/
 (FPHI) CO: Fountain Pharmaceuticals, Inc. ST: Florida IN: MTC SU: PER


CC-JS -- PH028 -- 7267 04/10/92 13:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 10, 1992
Words:302
Previous Article:FEDERAL REGULATORS ORDER RECEIVERSHIP FOR VIRGINIA THRIFT; DEPOSITS INSURED
Next Article:MERCK'S VASOTEC(R) RECEIVES NEW BROADENED HEART FAILURE INDICATION


Related Articles
FOUNTAIN PHARMACEUTICALS SIGNS AGREEMENT WITH BROCADES PHARMA
FOUNTAIN PHARMACEUTICALS SIGNS OPTION AGREEMENT
FOUNTAIN PHARMACEUTICALS ANNOUNCES INTENDED REGISTRATION OF ADDITIONAL SHARES
FOUNTAIN PHARMACEUTICALS ANNOUNCES REORGANIZATION OF MANAGEMENT
FOUNTAIN ANNOUNCES COMPLETION OF MANAGEMENT REORGANIZATION; DR. FOUNTAIN TO REJOIN THE COMPANY
FOUNTAIN ANNOUNCES COMPLETION OF MANAGEMENT REORGANIZATION; DR. FOUNTAIN TO REJOIN THE COMPANY
FOUNTAIN PHARMACEUTICALS ANNOUNCES SIGNIFICANT CONCERNS REGARDING NASDAQ LISTING AND CAPITAL RESOURCES
Fountain View Files Plan of Reorganization in Key Step to Emerge From Chapter 11; Received $150 Million Commitment in Exit Financing; Plan...
Fountain View Emerges From Chapter 11; $250 Million Refinancing Successfully Completed.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters